Zynex (ZYXI) and Its Competitors Financial Contrast

Zynex (NASDAQ: ZYXI) is one of 66 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Zynex to similar companies based on the strength of its profitability, dividends, earnings, institutional ownership, risk, analyst recommendations and valuation.

Insider & Institutional Ownership

29.6% of Zynex shares are owned by institutional investors. Comparatively, 46.5% of shares of all “Electromedical equipment” companies are owned by institutional investors. 50.5% of Zynex shares are owned by insiders. Comparatively, 18.6% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zynex and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zynex 18.08% 50.67% 35.56%
Zynex Competitors -270.31% -76.81% -16.07%

Risk and Volatility

Zynex has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Zynex’s competitors have a beta of 24.78, meaning that their average share price is 2,378% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zynex and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zynex 0 0 0 0 N/A
Zynex Competitors 344 1024 1727 92 2.49

As a group, “Electromedical equipment” companies have a potential upside of 5.14%. Given Zynex’s competitors higher probable upside, analysts clearly believe Zynex has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Zynex and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Zynex $45.47 million $9.49 million 47.93
Zynex Competitors $928.65 million $109.94 million 24.10

Zynex’s competitors have higher revenue and earnings than Zynex. Zynex is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Zynex Company Profile

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.